Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity.
Anthracyclines are among the most efficient drugs of cancer chemotherapy, but their use is limited by a significant risk of cardiotoxicity, which is still far from being understood. This study investigates whether impairment of mitochondrial creatine kinase (MtCK), a key enzyme in cellular energy metabolism, could be involved in anthracycline cardiotoxicity. We have analyzed the effects of three anthracyclines, doxorubicin, daunorubicin, and idarubicin, on two MtCK isoenzymes, sarcomeric/cardiac sMtCK and ubiquitous uMtCK, from human and chicken. Using surface plasmon resonance, gel filtration, and enzyme assays, we have quantified properties that are of basic importance for MtCK functioning in vivo: membrane binding, octameric state, and enzymatic activity. Anthracyclines significantly impaired all three properties with differences in dose-, time-, and drug-dependence. Membrane binding and enzymatic activity were already affected at low anthracycline concentrations (5-100 microM), indicating high clinical relevance. Effects on membrane binding were immediate, probably because of competitive binding of the drug to cardiolipin. In contrast, dissociation of MtCK octamers into dimers, enzymatic inactivation and cross-linking occurred only after hours to days. Different protection assays suggest that the deleterious effects were caused by oxidative damage, mainly affecting the highly susceptible MtCK cysteines, followed by generation of free oxygen radicals at higher drug concentrations. Enzymatic inactivation occurred mainly at the active site and involved Cys278, as indicated by experiments with protective agents and sMtCK mutant C278G. All anthracycline effects were significantly more pronounced for sMtCK than for uMtCK. These in vitro results suggest that sMtCK damage may play a role in anthracycline cardiotoxicity.
Tokarska-Schlattner
Malgorzata
M
Institute of Cell Biology, Swiss Federal Institute of Technology (ETH), Hönggerberg, Zürich, Switzerland.
Wallimann
Theo
T
Schlattner
Uwe
U
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D002308:Cardiolipins / Q000378:metabolism; D002645:Chickens; D003402:Creatine Kinase / Q000187:drug effects / Q000378:metabolism*; D052281:Creatine Kinase, Mitochondrial Form; D003630:Daunorubicin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D006321:Heart / Q000187:drug effects*; D006801:Humans; D015255:Idarubicin / Q000494:pharmacology; D007527:Isoenzymes / Q000187:drug effects / Q000378:metabolism*; D008958:Models, Molecular; D008970:Molecular Weight; D009206:Myocardium / Q000201:enzymology
D000903:Antibiotics, Antineoplastic; D002308:Cardiolipins; D007527:Isoenzymes; D004317:Doxorubicin; D003402:Creatine Kinase; D052281:Creatine Kinase, Mitochondrial Form; D015255:Idarubicin; D003630:Daunorubicin